ORGANOGENESIS HOLDINGS INC. Payments for Restructuring
ORGANOGENESIS HOLDINGS INC. (ORGO) reported Payments for Restructuring of $338.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForRestructuring · last filed 2026-02-26
- ORGANOGENESIS HOLDINGS INC. payments for restructuring for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- ORGANOGENESIS HOLDINGS INC. payments for restructuring for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- ORGANOGENESIS HOLDINGS INC. payments for restructuring for the quarter ending 2024-06-30 was $280.00K, a 57.77% decline year-over-year.
- ORGANOGENESIS HOLDINGS INC. payments for restructuring for the quarter ending 2024-03-31 was $624.00K, a 69.00% decline year-over-year.
- ORGANOGENESIS HOLDINGS INC. payments for restructuring for fiscal 2025 was $338.00K, a 62.61% decline from fiscal 2024.
- ORGANOGENESIS HOLDINGS INC. payments for restructuring for fiscal 2024 was $904.00K, a 77.86% decline from fiscal 2023.
- ORGANOGENESIS HOLDINGS INC. payments for restructuring for fiscal 2023 was $4.08M, a 3.77% decline from fiscal 2022.
- ORGANOGENESIS HOLDINGS INC. payments for restructuring for fiscal 2022 was $4.24M, a 97.03% increase from fiscal 2021.
| Period end | Payments for Restructuring 3 month | Payments for Restructuring 6 month | Payments for Restructuring 9 month | Payments for Restructuring 12 month |
|---|---|---|---|---|
| 2025-12-31 | $338.00K 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $280.00K derived: sum of 3 quarters · filed 2026-02-26 | $904.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $280.00K derived: sum of 2 quarters · filed 2024-11-12 | $904.00K 10-Q · filed 2024-11-12 | $1.93M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $280.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $904.00K 10-Q · filed 2024-08-08 | $1.93M derived: sum of 3 quarters · filed 2026-02-26 | $2.31M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $624.00K 10-Q · filed 2024-05-09 | $1.65M derived: sum of 2 quarters · filed 2026-02-26 | $2.03M derived: sum of 3 quarters · filed 2026-02-26 | $2.69M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.41M derived: sum of 2 quarters · filed 2026-02-26 | $2.07M derived: sum of 3 quarters · filed 2026-02-26 | $4.08M 10-K · filed 2026-02-26 |
| 2023-09-30 | $380.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $1.04M derived: sum of 2 quarters · filed 2024-11-12 | $3.06M 10-Q · filed 2024-11-12 | $3.72M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $663.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $2.68M 10-Q · filed 2024-08-08 | $3.34M derived: sum of 3 quarters · filed 2024-08-08 | $3.51M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $2.01M 10-Q · filed 2024-05-09 | $2.68M derived: sum of 2 quarters · filed 2024-05-09 | $2.84M derived: sum of 3 quarters · filed 2024-05-09 | $2.96M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $668.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $830.00K derived: sum of 2 quarters · filed 2024-02-29 | $944.00K derived: sum of 3 quarters · filed 2024-02-29 | $4.24M 10-K · filed 2024-02-29 |
| 2022-09-30 | $162.00K 10-Q · filed 2022-11-09 | $276.00K derived: sum of 2 quarters · filed 2022-11-09 | $3.58M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $114.00K 10-Q · filed 2022-08-09 | $3.41M 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | $3.30M 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | $2.15M 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |